Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study
Data files
Sep 29, 2023 version files 265.53 KB
Abstract
Objectives: Sarcopenia is a known risk factor for non-alcoholic fatty liver disease (NAFLD). Studies evaluating the association between the fat-to-muscle ratio (FMR) and NAFLD are limited. Therefore, the aim of our study was to investigate the association between FMR and NAFLD.
Design: A retrospective study was conducted on the individuals who underwent health examination in Wuhan Union Hospital between January 2020 and November 2021. Clinical data were collected from electronic medical records.
Setting: Our study was conducted in a hospital in China.
Participants: A total of 1,592 participants aged ≥40 years who underwent body composition analysis and liver ultrasonography were retrospectively reviewed.
Primary outcome measures: Liver ultrasonography was used to assess liver steatosis, and the Fibrosis-4 Index (FIB-4) was used to calculate the risk scores for liver fibrosis. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk prediction model was used to calculate ASCVD risk scores.
Results: The FMR was significantly higher in individuals with NAFLD than in those without NAFLD (P<0.001). The prevalence of NAFLD gradually increased from FMR tertile 1 (reference) to tertile 2 (OR=1.49, 95% CI: 1.13–1.97) and tertile 3 (OR=2.85, 95% CI: 2.08–3.90). In addition, patients with NAFLD in FMR tertile 3 had a significantly higher risk of liver fibrosis (OR=4.48, 95% CI: 2.12–9.50) and ASCVD (OR=4.63, 95% CI: 2.62–8.19) than those in FMR tertile 1 after adjustment for multiple confounders.
Conclusion: In this study, we found a significant association between FMR and NAFLD. A higher FMR indicates a higher risk of NAFLD in the study population and a higher risk of liver fibrosis and ASCVD in NAFLD patients.
README: Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study
https://doi.org/10.5061/dryad.7d7wm3809
Description of the data and file structure
NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; FMR, fat-to-muscle ratio; PLT, platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; UA, uric acid; FBG, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; ASCVD, atherosclerotic cardiovascular disease; WBC, white blood cell count; HB, hemoglobin.
- Sex: 0 female, 1 male
- Age (years): 1 40~49, 2 50~59, 3 60~69, 4 70~79
- FMR tertiles: 1 FMR tertile 1, 2 FMR tertile 2, 3 FMR tertile 3
- Tobacco use: 0 no, 1 yes
- Alcohol use: 0 no, 1 yes
- Hypertension: 0 no, 1 yes
- Diabetes: 0 no, 1 yes
- NAFLD: 0 no, 1 yes
Units of measurement
- Age (years)
- BMI (kg/m2)
- PLT (109/L)
- ALT (U/L)
- AST (U/L)
- TC (mmol/L)
- TG (mmol/L)
- HDL-C (mmol/L)
- LDL-C (mmol/L)
- UA (umol/L)
- FBG (mmol/L)
- SBP (mmHg)
- DBP (mmHg)
Sharing/Access information
This is a section for linking to other ways to access the data, and for linking to sources the data is derived from, if any.
Links to other publicly accessible locations of the data:
Data was derived from the following sources:
Code/Software
This is an optional, freeform section for describing any code in your submission and the software used to run it.
All analyses were performed using SPSS version 25 (IBM, Armonk, NY, USA).
Describe any scripts, code, or notebooks (e.g., R, Python, Mathematica, MatLab) as well as the software versions (including loaded packages) that you used to run those files. If your repository contains more than one file whose relationship to other scripts is not obvious, provide information about the workflow that you used to run those scripts and notebooks.
Methods
The data was collected and entered manually, and missing data was filled in using SPSS's series mean method.